4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones


EMERYVILLE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2025 financial results, provided operational highlights and outlined expected upcoming milestones.

Excerpt from:
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Related Posts